Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis
المؤلفون المشاركون
Zheng, Peng
Liang, Chunmin
Ren, Li
Zhu, Dexiang
Feng, Qingyang
Chang, Wenju
He, Guodong
Ye, Lechi
Chen, Jingwen
Lin, Qi
Yi, Tuo
Ji, Meiling
Niu, Zhengchuan
Jian, Mi
Wei, Ye
Xu, Jianmin
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-14، 14ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-09-16
دولة النشر
مصر
عدد الصفحات
14
التخصصات الرئيسية
الملخص EN
Purpose.
We aimed to identify new predictive biomarkers for cetuximab in first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC).
Methods.
The study included patients with KRAS wild-type unresectable liver-limited mCRC treated with chemotherapy with or without cetuximab.
Next-generation sequencing was done for single nucleotide polymorphism according to custom panel.
Potential predictive biomarkers were identified and integrated into a predictive model within a training cohort.
The model was validated in a validation cohort.
Results.
Thirty-one of 247(12.6%) patients harbored RAS mutations.
In training cohort (N=93), six potential predictive genes, namely, ATP6V1B1, CUL9, ERBB2, LY6G6D, PTCH1, and RBMXL3, were identified.
According to predictive model, patients were divided into responsive group (n=66) or refractory group (n=27).
In responsive group, efficacy outcomes were significantly improved by addition of cetuximab to chemotherapy.
In refractory group, no benefit was observed.
Interaction test was significant across all endpoints.
In validation cohort (N=123), similar results were also observed.
Conclusions.
In the first-line treatment of mCRC, the predictive model integrating six new predictive mutations divided patients well, indicating a promising approach to further refine patient selection for cetuximab on the basis of RAS mutations.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Zheng, Peng& Liang, Chunmin& Ren, Li& Zhu, Dexiang& Feng, Qingyang& Chang, Wenju…[et al.]. 2018. Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. Journal of Oncology،Vol. 2018, no. 2018, pp.1-14.
https://search.emarefa.net/detail/BIM-1195803
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Zheng, Peng…[et al.]. Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. Journal of Oncology No. 2018 (2018), pp.1-14.
https://search.emarefa.net/detail/BIM-1195803
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Zheng, Peng& Liang, Chunmin& Ren, Li& Zhu, Dexiang& Feng, Qingyang& Chang, Wenju…[et al.]. Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. Journal of Oncology. 2018. Vol. 2018, no. 2018, pp.1-14.
https://search.emarefa.net/detail/BIM-1195803
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1195803
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر